TAYSHA GENE THERAPIES INC
TSHANASDAQTrading Snapshot
- Day Range
- $4.94 – $5.07
- 52-Week Range
- $3.10 – $7.30
- Volume
- $3.36B
- Avg Volume
- $2.64B
- Shares Outstanding
- 319.9M
- Next Earnings
- Nov 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $2M
- P/E Ratio
- -11.8
- P/S Ratio
- 291.0x
- EPS (TTM)
- $-0.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +56.0%
Why Investors Own TSHA
- ✓High-growth profile — revenue up +38.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TAYSHA GENE THERAPIES INC
TSHA
StockOtter · stockotter.spaceAbout TAYSHA GENE THERAPIES INC
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivo
These 3 Risky Stocks Could Be Sitting on 100% Upside
With industrials, energy, and tech stocks undergirding an S&P 500 that is hovering near all-time highs, investors looking for high-upside companies may be resigned to more speculative plays. While it's true that some lon
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies
Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA
Bank of America Corp DE raised its stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) by 45.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund own
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license appli